Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-κB-dependent down-regulation of vascular cell adhesion molecule-1 expression

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 53-58

  Gao, Ling ^a   Wang, Furong ^a   Wang, Bo ^b   Gong, Bendi ^c   Zhang, Jie ^a   Zhang, Xiumei ^d   Zhao, Jiajun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; STREPTOZOCIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GENE CONTROL; GENETIC TRANSCRIPTION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR DISEASES;

EID: 33745287776     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.101444     Document Type: Article

References (32)

1. Ahn CW, Lee HC, Park SW, Song YD, Huh KB, Oh SJ, Kim YS, Choi YK, Kim JM, and Lee TH (2001) Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 52:45-53.
2. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, and Dandona P (2001) Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 86:3250-3256.
3. Altannavch TS, Roubalova K, Kucera P, and Andel M (2004) Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res 53:77-82.
4. Bagrov YY, Manusova NB, Egorova IA, Fedorova OV, and Bagrov AY (2005) Endogenous digitalis-like ligands and Na/K-ATPase inhibition in experimental diabetes mellitus. Front Biosci 10:2257-2262.
5. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, et al. (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50:2792-2808.
6. Brondum E, Nilsson H, and Aalkjaer C (2005) Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm Metab Res 37:56-60.
7. Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G, and Staels B (2002) DNA binding-independent induction of IκBα gene transcription by PPARα. Mol Endocrinol 16:1029-1039.
8. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, and Wagner DD (1998) The combined role of P- and E-selectins in atherosclerosis. J Clin Investig 102:145-152.
9. Duan W, Paka L, and Pillarisetti S (2005) Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. Cardiovasc Diabetol 4:16.
10. Erdmann E (2005) Diabetes and cardiovascular risk markers. Curr Med Res Opin 21 (Suppl):S21-S28.
11. Esposito C, Fasoli G, Plati AR, Bellotti N, Conte MM, Cornacchia F, Foschi A, Mazzullo T, Semeraro L, and Canton A Dal (2001) Long-term exposure to high glucose up-regulates VCAM-induced endothelial cell adhesiveness to PBMC. Kidney Int 59:1842-1849.
12. Ishibashi Y and Nishikawa A (2003) Role of nuclear factor-κB in the regulation of intercellular adhesion molecule 1 after infection of human bronchial epithelial cells by Bordetella pertussis. Microb Pathog 35:169-177.
13. Jude EB, Douglas JT, Anderson SG, Young MJ, and Boulton AJ (2002) Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med 13:185-189.
14. Kouroedov A, Eto M, Joch H, Volpe M, Luscher TF, and Cosentino F (2004) Selective inhibition of protein kinase C beta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 110:91-96.
15. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, and Hong KW (2005) Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313:502-509.
16. Minhajuddin M, Fazal F, Bijli KM, Amin MR, and Rahaman A (2005) Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-(kappa)B activation in endothelial cells. J Immunol 174:5823-5829.
17. Mitsuhashi N, Tanaka Y, Kubo S, Ogawa S, Hayashi C, Uchino H, Shimizu T, Watada H, Kawasumi M, Onuma T, et al. (2004) Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J 51:545-550.
18. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, and Kikkawa R (1997) Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-α in vascular endothelial cells. Horm Metab Res 29:491-495.
19. Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, Okouchi M, and Itoh M (2004) Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 68:119-125.
20. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, and Kasayama S (2001) Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF- κB binding to its recognition sequence. Atherosclerosis 158:121-128.
21. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, and Hong KW (2005) Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and MCP-1 expression via LOX-1 receptor activation. J Pharmacol Exp Ther 312:1241-1248.
22. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, and Srivastava SK (2004) Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 53:2910-2920.
23. Rao PV, Pugazhenthi S, and Khandelwal RL (1995) The effects of streptozotocin-induced diabetes and insulin supplementation on expression of the glycogen phosphorylase gene in rat liver. J Biol Chem 270:24955-24960.
24. Renier G, Mamputu JC, and Serri O (2003) Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 52(Suppl 1):13-18.
25. Ribau JC, Hadcock SJ, Teoh K, DeReske M, and Richardson M (1999) Endothelial adhesion molecule expression is enhanced in the aorta and internal mammary artery of diabetic patients. J Surg Res 85:225-233.
26. Seki N, Hashimoto N, Sano H, Horiuchi S, Yagui K, Makino H, and Saito Y (2003) Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism 52:1558-1563.
27. Serkkola E and Hurme M (1993) Activation of NF-κB by cAMP in human myeloid cells. FEBS Lett 334:327-330.
28. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, Kajimoto Y, Tsujino T, Hakui N, Matsumoto M, and Hori M (2002) A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia 45:188-194.
29. Szaszi K, Jones JJ, Nathens AB, Lo AY, Kapus A, and Rotstein OD (2005) Glutathione depletion inhibits lipopolysaccharide-induced intercellular adhesion molecule 1 synthesis. Free Radic Biol Med 38:1333-1343.
30. Wada J, Shikata K, Makino H, Morioka S, Hirata K, Ota K, Tamatani T, Miyasaka M, Horiuchi T, Noji S, et al. (1996) The critical role of intercellular adhesion molecule-1 in Masugi nephritis in rats. Nephron 73:264-272.
31. Wang Z, Zhao JJ, Gao L, and Zhang YQ (2002) Effect of cilostazol on adhesion molecules of STZ-induced diabetic rats. Chin Med J 82:729-731.
32. Zuccollo A, Shi CM, Mastroianni R, Maitland KA, Weisbrod RM, Zang MW, Xu SQ, Jiang BB, Oliver JM, Cayatte AJ, et al. (2005) The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112:3001-3008.